Clinical Trial

Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients

Study acronym: STRIDE
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
A PROSPECTIVE, MULTI-CENTER, PHASE 4, SINGLE ARM STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-05-21; most recent amendment 2025-11-20.
Status change: Not Yet Recruiting → Recruiting 2025-01-27
Trial Details
NCT Number NCT06429761
Lead Sponsor AstraZeneca
Conditions BREAST CANCER
Enrollment 100 participants
Start Date 2025-01-02
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-24